Natalizumab concentrations during pregnancy in three patients with multiple sclerosis: A clinical commentary

Mult Scler. 2022 Feb;28(2):326-327. doi: 10.1177/13524585211069922.

Authors

Ruth Dobson¹, Karen Chung²

Affiliations

¹ Preventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, UK/Department of Neurology, The Royal London Hospital, London, UK.
² Department of Neuro- Inflammation, National Hospital for Neurology and Neurosurgery, London, UK.

No abstract available

Publication types

Comment

MeSH terms

Female
Humans
Immunologic Factors / adverse effects
Multiple Sclerosis* / drug therapy
Multiple Sclerosis, Relapsing-Remitting*
Natalizumab / adverse effects
Pregnancy

Substances

Immunologic Factors
Natalizumab